Korean J Intern Med.
2015 Jan;30(1):23-26. 10.3904/kjim.2015.30.1.23.
Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
- Affiliations
-
- 1Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
- 2Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. jsleemd@paik.ac.kr
- KMID: 2129658
- DOI: http://doi.org/10.3904/kjim.2015.30.1.23
Abstract
- No abstract available.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
- Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
- Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles
- Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
- A Case of Tenofovir-associated Fanconi Syndrome in Patient with Chronic Hepatitis B
